Cephalon, A Target Itself, To Acquire Remainder Of Australian ChemGenex
This article was originally published in PharmAsia News
Executive Summary
Cephalon Inc. announced March 29 that it has struck an agreement with the Australia-based biopharma ChemGenex Pharmaceuticals Ltd. to pay A$159 million ($US $163 million) for the piece of the company it doesn't already own